## Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

SIGA TECHNOLOGIES INC Form 8-K February 15, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 15, 2005

SIGA Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 0-23047 13-3864870

(State or other Jurisdiction of (Commission File (I.R.S. Employer Incorporation or Organization) Number) Identification Number)

(212) 672-9100

-----

(Registrant's telephone number, including area code)

ITEM 8.01. Other Events.

On February 15, 2005, SIGA Technologies, Inc., a Delaware corporation, issued a press release pursuant to which it announced that SIGA and TransTech Pharma, Inc., a privately held Delaware corporation, received a \$2.7 million challenge grant from the National Institutes of Health to support the development of protease inhibitors to treat orthopoxvirus infections, such as smallpox and monkeypox. The grant award will be used to fund SIGA and TransTech Pharma's joint research efforts directed toward the discovery, optimization, and advancement of lead drug candidates for smallpox and biowarfare defense. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated in this Item 8.01 by reference.

ITEM 9. Financial Statements and Exhibits

(c) Exhibits

## Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

Exhibit No. Description

99.1 Press Release dated February 15, 2005.

2

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

-----

Thomas N. Konatich Chief Financial Officer

Date: February 15, 2005

3

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release dated February 15, 2005

4